published meta-analysis   sensitivity analysis   studies

azithromycin in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsPRINCIPLE, 2021 1.65 [0.03; 83.12] 1.65[0.03; 83.12]PRINCIPLE, 202110%1,323NAnot evaluable hospitalization or deathdetailed resultsHinks (ATOMIC2), 2021 0.91 [0.43; 1.92] 0.91[0.43; 1.92]Hinks (ATOMIC2), 202110%292NAnot evaluable A EFFACER PCR-negative (end of follow-up)detailed resultsHinks (ATOMIC2), 2021 0.91 [0.57; 1.46] 0.91[0.57; 1.46]Hinks (ATOMIC2), 202110%295NAnot evaluable clinical improvementdetailed resultsPRINCIPLE, 2021 1.08 [0.95; 1.23] 1.08[0.95; 1.23]PRINCIPLE, 202110%1,323NAnot evaluable clinical improvement (14-day)detailed resultsACTION, 2021 1.01 [0.75; 1.37] 1.01[0.75; 1.37]ACTION, 202110%263NAnot evaluable clinical improvement (time to event analysis only)detailed resultsPRINCIPLE, 2021 1.08 [0.95; 1.23] 1.08[0.95; 1.23]PRINCIPLE, 202110%1,323NAnot evaluable hospitalizationdetailed resultsHinks (ATOMIC2), 2021 0.95 [0.46; 1.96] PRINCIPLE, 2021 0.94 [0.50; 1.75] 0.94[0.59; 1.51]Hinks (ATOMIC2), 2021, PRINCIPLE, 202120%1,618moderatenot evaluable mechanical ventilationdetailed resultsPRINCIPLE, 2021 0.50 [0.10; 2.60] 0.50[0.10; 2.60]PRINCIPLE, 202110%1,121NAnot evaluable ICU admissiondetailed resultsPRINCIPLE, 2021 0.76 [0.18; 3.18] 0.76[0.18; 3.18]PRINCIPLE, 202110%1,120NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-29 09:24 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 619 - roots T: 290